FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug
INDIANAPOLIS (AP) — Federal regulators put off a decision on whether to approve an Eli Lilly Alzheimer’s drug by making an unusual request to have outside advisers look at the treatment.